- Home
- TOVX vs KTTA Comparison
TOVX vs KTTA Comparison
Compare TOVX & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- KTTA
- Stock Information
- Founded
- TOVX 2001
- KTTA 2020
- Country
- TOVX United States
- KTTA United States
- Employees
- TOVX N/A
- KTTA N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- KTTA Health Care
- Exchange
- TOVX Nasdaq
- KTTA Nasdaq
- Market Cap
- TOVX 4.5M
- KTTA 5.1M
- IPO Year
- TOVX 2006
- KTTA 2021
- Fundamental
- Price
- TOVX $0.41
- KTTA $0.77
- Analyst Decision
- TOVX Hold
- KTTA
- Analyst Count
- TOVX 1
- KTTA 0
- Target Price
- TOVX N/A
- KTTA N/A
- AVG Volume (30 Days)
- TOVX 1.0M
- KTTA 182.5K
- Earning Date
- TOVX 11-11-2025
- KTTA 11-12-2025
- Dividend Yield
- TOVX N/A
- KTTA N/A
- EPS Growth
- TOVX N/A
- KTTA N/A
- EPS
- TOVX N/A
- KTTA N/A
- Revenue
- TOVX N/A
- KTTA N/A
- Revenue This Year
- TOVX N/A
- KTTA N/A
- Revenue Next Year
- TOVX N/A
- KTTA N/A
- P/E Ratio
- TOVX N/A
- KTTA N/A
- Revenue Growth
- TOVX N/A
- KTTA N/A
- 52 Week Low
- TOVX $0.37
- KTTA $0.65
- 52 Week High
- TOVX $4.29
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- TOVX 46.51
- KTTA 51.25
- Support Level
- TOVX $0.38
- KTTA $0.74
- Resistance Level
- TOVX $0.45
- KTTA $0.81
- Average True Range (ATR)
- TOVX 0.02
- KTTA 0.06
- MACD
- TOVX 0.00
- KTTA -0.00
- Stochastic Oscillator
- TOVX 44.00
- KTTA 36.73
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).